What is worth measuring in patients with COPD?
Keywords:
COPD, chronic bronchiolitis, emphysema, multidimensional risk assessment, patient’s managementAbstract
A personalized approach to management of a COPD patient is currently required due to heterogeneity of this disorder. A functional evaluation of each COPD patient is a fundamental part of the process to achieve this objec- tive and should require a rational step-by-step procedure starting from the etiology of COPD, determination of the predominant underlying disease, assessment of risk severity, therapeutic role of ICS and finally monitoring of disease activity and its impact on the patient’s life under the chosen treatment. Aim of this review is to indicate a series of easy sequential measurements that are worth to have for obtaining all this information crucial to taking care of a patient with a new diagnosis of COPD.
References
1. Miravittles M, Dirksen A, Ferrarotti I, Koblizek V, Lange P, Mahadeva R, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in alfa-1-antitrypsin deficiency. Eur Respir J 2017;50(5).
2. Lee JH, Lee YK, Kim EK, Kim TH. Responses to inhaled long-acting beta-agonist and corticosteroids to COPD subtype. Respir Med 2010;104:542-9.
3. Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, Hasegawa M, et al. AJRCCM 2012;185:44-52.
4. Johannessen A. Skorge TD, Bottai M, Grydeland TB, Nilsen RM, Coxson H, et al. Mortality by level of emphysema and airway wall thickness. AJRCCM 2013;187:602-8.
5. Tantucci C, Pini L. COPD: it is time to change! Int J of COPD 2015;10:2451-7.
6. Occhipinti M, Paoletti M, Bartholmai BJ, Rajagopalan S, Karwoski RA, Nardi C, et al. Spirometric assessment of emphysema presence and severity as measured by quantitative CT and CT-based radiomics in COPD. Respir Res 2019;20:101.
7. Occhipinti M, Paoletti M, Crapo JD, Make BJ, Lynch DA, Brusasco V, et al. Validation of a method to assess emphysema severity by spirometry in the COPDgene study. Respir Res 2020;21:103.
8. Tantucci C, Pini L. COPD: Inhaled corticosteroids in COPD: trying to make a long story short. Int J of COPD 2020;15:821-9.
9. Divo M, Cote C, deTorres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. AJRCCM 2012;186:155-61.
10. Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J 2015;45:525-37.
11. Agusti A, MacNee W. The COPD control panel: towards personalised medicine in COPD. Thorax 2013;68:687-90.
12. Sing D, Criner GJ, Naya I, Jones PW, Tombs L, Lipson A, et al. Measuring disease activity in COPD: is clinically important deterioration the answer? Respir Res 2020;21:134-47.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Mattioli 1885 has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
How to Cite
